Drug Profile
Research programme: RNAi cancer therapeutics - Calando
Alternative Names: CALAA-02Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Calando Pharmaceuticals; National Cancer Institute (USA)
- Class Small interfering RNA
- Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Neuroblastoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV, Injection)
- 06 Apr 2016 Arrowhead Research Corporation is now called Arrowhead Pharmaceuticals
- 02 Mar 2012 Preclinical development is ongoing in USA